(VYGR) Promotes Jeff Goater to CFO

CAMBRIDGE, Mass., Feb. 02, 2016  — Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced it has promoted Jeff Goater, former senior vice president of finance and business development, to chief financial officer. In this new role, Mr. Goater will be responsible for overseeing the company’s financial strategy and planning, investor and public relations, corporate operations and business development.

“Jeff’s exceptional leadership has been and will continue to be instrumental in identifying strategic growth opportunities for Voyager,” said Steven Paul, M.D. president and CEO of Voyager Therapeutics. “Since the company’s inception in 2014, Jeff has been a highly regarded member of the leadership team and this promotion is a reflection of his significant contributions to the company’s growth, including Voyager’s successful initial public offering in November 2015.”

Mr. Goater has more than 15 years of business development and financial experience in the biotech industry. He has served in several executive roles since Voyager’s launch in 2014, including senior vice president of finance and business development and vice president of business development. Prior to Voyager, Mr. Goater spent nearly a decade on Wall Street, most recently as a managing director at Evercore Partners, focused on strategic advisory in the life sciences sector. While at Evercore, he advised on more than $100 billion in M&A and licensing transactions. Mr. Goater began his Wall Street career as an equity research analyst at Cowen and Company, covering the biopharmaceutical sector. Prior to Cowen, he worked in biotech business development and began his career as a research scientist in the fields of musculoskeletal biology and gene therapy. Mr. Goater holds a B.A. in biology, an M.S. in pathology/molecular medicine, an M.S. in microbiology/immunology and an M.B.A., all from the University of Rochester.

About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities law. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the initiation, timing, progress and results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully complete, clinical trials, its ability to continue to develop its product engine, its ability to add new programs to its pipeline, and the timing or likelihood of regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s final prospectus for its initial public offering filed with the Securities and Exchange Commission, as updated by its future filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Investor Relations:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com

Media:
Katie Engleman
Pure Communications, Inc. 
910-509-3977
Katie@purecommunicationsinc.com

(ADAP) & (GSK) Expand Strategic Immunotherapy Collaboration

• Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trials
• Creates opportunity for up to eight combination studies

LONDON, PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T- cell receptor (TCR) engineered T-cell therapy to treat cancer, and GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1, toward pivotal trials in synovial sarcoma.

Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.

“We are delighted to broaden our collaboration with GSK, which is also fully committed to the development of this revolutionary T-cell therapy,” commented James Noble, Adaptimmune’s Chief Executive Officer. “We believe that our affinity enhanced T-cell programs have the potential to deliver important clinical benefit to cancer patients, and it is therefore essential that we accelerate our efforts to meet their needs. We are working closely with GSK to expedite development of our affinity enhanced T-cell therapy targeting NY-ESO, and if we succeed in generating pivotal data consistent with that of our ongoing studies, we believe it has the potential to be the first engineered T-cell therapy to reach the market.”

Dr. Axel Hoos, SVP Oncology R&D GSK said, “At GSK we’re progressing a pipeline of immuno-oncology therapies to stimulate anti-tumor immunity in patients. As we highlighted to investors at our R&D event last year, this Adaptimmune collaboration is a key element of that pipeline and is part of a comprehensive program for cell and gene therapy. With this expanded collaboration, we have the opportunity to accelerate the lead program in synovial sarcoma toward pivotal trials and also to investigate several other tumor types and combine the T-cell therapy with immune-modulating therapies such as checkpoint inhibitors.”

Under the terms of the expanded agreement, the companies will accelerate the development of Adaptimmune’s NY-ESO therapy into pivotal studies in synovial sarcoma and will explore development in myxoid round cell liposarcoma. Additionally, the companies may initiate up to eight proof-of-principle studies exploring combinations with other therapies, including checkpoint inhibitors.

According to the expanded development plan, the studies will be conducted by Adaptimmune with GSK effectively funding the pivotal studies and sharing the costs of the combination studies via a success based milestone structure.

Previous guidance relating to the collaboration disclosed potential cash payments to Adaptimmune of approximately $350m over the first 7 years from 2014 in relation to NY-ESO and two further programs. Given the changes announced today, and the advances made across the collaboration, Adaptimmune is updating and expanding this disclosure. Under the terms of the expanded agreement, the potential development milestones Adaptimmune is eligible to receive solely in relation to the NY-ESO program could amount to approximately $500 million, excluding previously received payments, if GSK exercises its option and successfully develops NY-ESO in more than one indication and more than one Human Leukocyte Antigen (HLA) type.  In addition, Adaptimmune would receive tiered sales milestones and, as previously disclosed, mid-single to low double digit royalties on worldwide net sales. GSK has the right to nominate up to four additional targets in due course and Adaptimmune is eligible to receive further significant undisclosed milestone payments in relation to these earlier stage target programs.

Adaptimmune has also reiterated its prior cash burn guidance, which remains unchanged as the majority of the expansion and acceleration costs will be funded by GSK. For the full year 2016, the company expects its cash burn to be between $80 and $100 million, excluding cash burn associated with business development activities, and expects its cash position at December 31, 2016, including cash, cash equivalents, and short term deposits, to be at least $150 million.

About affinity enhanced T-cell candidates

Adaptimmune’s affinity enhanced T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response. Using its proprietary technology, Adaptimmune has created a pipeline of affinity enhanced T-cell therapies targeting certain antigens, including cancer testis antigens such as NY-ESO.  NY-ESO-1 is one of the best-characterized and most immunogenic cancer testis antigens, and is frequently expressed by tumors of different origins and in advanced tumors. The company’s trials in the NY-ESO-1 program in multiple myeloma, melanoma, sarcoma and ovarian cancer continue to generate encouraging results.

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D ‘Risk factors’ in the company’s Annual Report on Form 20-F for 2014.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).  These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission on  October 13, 2015. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T:  (215) 825-9306  
E: will.roberts@adaptimmune.com

Margaret Henry 
Head of PR 
T: +44 (0)1235 430036 
Mob: +44 (0)7710 304249 
E: margaret.henry@adaptimmune.com

(HNSN) Announces FDA Clearance of the Magellan(TM) Robotic Catheter eKit

(AVXL) to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016

NEW YORK, Feb. 02, 2016  — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference.

Dr. Missling’s presentation is scheduled to take place on Tuesday, February 9, 2016 at 1:30 p.m. ET at the Waldorf-Astoria Hotel, Conrad Suite, in New York, NY.  Investors may view Dr. Missling’s presentation via live webcast (http://www.veracast.com/webcasts/bio/ceoinvestor2016/85223495157.cfm) or access an archived version via Anavex.com.

The 18th Annual BIO CEO & Investor Conference is hosted by the Biotechnology Industry Organization. It is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept^®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in convulsive epileptic animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Shareholder & Media Relations
Toll-free: 1-866-505-2895
Outside North America: +1 (416) 489-0092
Email: ir@anavex.com
www.anavex.com

(COYN) COPsync911™ Implemented at Nichols College

Nichols is First College in Massachusetts to Use the Threat-Alert Protection System

DALLAS, Feb. 02, 2016  — COPsync, Inc. (NASDAQ:COYN), which operates the nation’s largest law enforcement real-time, in-car information sharing, communication and data interoperability network, announced today that Nichols College in Dudley, Mass., will be the first college in Massachusetts to implement the COPsync911 threat-alert system.

While the threat-alert system has already been implemented in several on-campus buildings, Nichols is expanding the installation to include a number of new on-campus buildings.

Nichols College is now part of an increasing number of municipalities that have joined the COPsync911 network as the system continues to be adopted across the nation. The COPsync911 system is activated by school faculty and staff when a threatening situation arises, and allows the employees to send an immediate and silent alert to all other employees, the local law enforcement dispatch center, all patrol cars and on-duty law enforcement officers, even if they are away from their patrol car.

Ronald A. Woessner, CEO of COPsync said, “We are excited to welcome our first college campus in Massachusetts to the COPsync911 threat-alert system as we move forward with the nationwide rollout of this important service. Nichols College is a thought leader in the area of school safety, and its adoption of COPsync911 paves the way for further expansion throughout New England. The College now joins the growing family of municipalities in the northeastern United States — including Maine, New Hampshire, Massachusetts, and Rhode Island — that are part of the COPsync911 network and have prioritized the safety of their students, staff, and faculty.”

Nichols College Chief Information Officer Kevin Brassard said: “Ensuring the safety of Nichols College’s student body of over 1,200 students requires a concerted and coordinated effort among law enforcement and college staff and faculty. We have implemented a multi-pronged approach to the safety of our campus that includes the COPsync911 threat-alert system. We are proud to provide an environment where our students can thrive as learners, thinkers, and citizens.”

About COPsync, Inc.

COPsync, Inc. (COYN) is a technology company that improves communication between and among law enforcement officers and agencies from differing jurisdictions to help them prevent and respond more quickly to crime. The COPsync Network™ connects law enforcement officers and agencies to a common communications system, which gives officers instant access to actionable, mission-critical data and enables them to share information and communicate in real-time with other officers and agencies, even those hundreds and thousands of miles away. The Network’s companion, COPsync911™ threat-alert system, enables schools, courts, hospitals, government buildings, energy, telecommunications and other potentially at-risk facilities to automatically and silently send threat-alerts directly to local law enforcement officers in their patrol cars in the event of a crisis, thereby speeding first responder response times and saving minutes when seconds count. The COPsync Network saves officer and citizen lives, reduces unsolved crimes and assists in apprehending criminals and interdicting criminal behavior — through such features as a nationwide officer safety alert system, GPS/auto vehicle location and distance-based alerts for crimes in progress, such as school crisis situations, child abductions, bank robberies and police pursuits. The COPsync Network also eliminates manual processes and increases officer productivity by enabling officers to write electronic tickets, accident reports, DUI forms, arrest forms and incident and offense reports. The company also sells VidTac®, an in-vehicle, software-driven video system for law enforcement. Visit www.copsync.com and www.copsync911.com for more information.

About Nichols College

Nichols College is a college of choice for business and leadership education as a result of its distinctive career-focused and leadership-based approaches to learning, both in and out of the classroom. Founded in 1815, Nichols transforms today’s students into tomorrow’s leaders through a dynamic, career-focused business and professional education. Nichols serves students interested primarily in a comprehensive business education that is supported by a strong liberal arts curriculum. For more information about Nichols College, please visit www.nichols.edu.

Contacts
For COPsync:
Ronald A. Woessner
Chief Executive Officer
972-865-6192
invest@copsync.com

Media:
Fred Sommer
Senior Consultant
Investor Relations
Ascendant Partners, LLC.
732-410-9810
fred@ascendantpartnersllc.com

College:
Lorraine U. Martinelle
Director of Public Relations
Nichols College
Dudley, Mass. 
508-213-2219
Lorraine.martinelle@nichols.edu

(MGI) and Walmart Announce New Three-Year Agreement

All MoneyGram services to continue at more than 4,000 Walmart locations

DALLAS, Feb. 1, 2016  — MoneyGram (NASDAQ: MGI) announced today the extension of their more than 17-year relationship with Walmart. This new three-year agreement, which begins on Feb. 1, continues MoneyGram’s domestic and international money transfer service as well as its bill pay and money order products at Walmart’s more than 4,000 locations in the U.S. and Puerto Rico. Walmart customers can also continue to access MoneyGram services through Walmart.com to send and receive money.

“We are extremely pleased to extend our relationship with Walmart for an additional three years,” said Alex Holmes, MoneyGram CEO. “For nearly two decades now, MoneyGram and Walmart have worked side by side to make money transfers and other financial services affordable and convenient for our customers.”

“Leveraging our size and scale to take on big challenges and create better ways to serve our customers is something we’re always working on. MoneyGram is a great provider in helping us deliver results that matter to our customers, offering innovative products and services that help them better manage their finances for less,” said Kirsty Ward, Walmart Senior Director, U.S. Financial Services.

Walmart and MoneyGram are committed to ongoing innovation in order to meet the evolving needs of the customer. Both companies will continue to make investments in marketing, technology and product development, including the roll-out of a redesigned online experience.

“MoneyGram is committed to fully understanding the expectations of our customers and agents and to enhancing their money transfer experience,” said Holmes. “This is a very dynamic industry and we are constantly looking to offer our customers new and better ways to send and receive money.”

#moneygramnews

About MoneyGram International, Inc.
MoneyGram is a global provider of innovative money transfer and payment services and is recognized worldwide as a financial connection to friends and family. Whether online, or through a mobile device, at a kiosk or in a local store, we connect consumers any way that is convenient for them. We also provide bill payment services, issue money orders and process official checks in select markets. More information about MoneyGram International, Inc. is available at moneygram.com.

Forward-Looking Statements
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to, among other things, the financial condition, results of operations, plans, objectives, future performance and business of MoneyGram and its subsidiaries. Forward-looking statements can be identified by words such as “believes,” “estimates,” “expects,” “projects,” “plans,” “intends,” “continues,” “will,” “should,” “could,” “would,” “may,” “goals,” “anticipates” and other similar expressions. These forward-looking statements speak only as of the date they are made, and MoneyGram undertakes no obligation to publicly update or revise any forward-looking statement for any reason, whether as a result of new information, future events or otherwise, except as required by federal securities law. These forward-looking statements are based on management’s current expectations, beliefs and assumptions and are subject to certain risks, uncertainties and changes in circumstances due to a number of factors. These factors include, but are not limited to: our ability to compete effectively; our ability to maintain key agent or biller relationships, or a reduction in business or transaction volume from these relationships, including our largest agent, Walmart, through the introduction by Walmart of a competing “white label” branded money transfer product or otherwise; the impact of our U.S.-to-U.S. pricing strategy; our ability to manage fraud risks from consumers or agents; the ability of us and our agents to comply with U.S. and international laws and regulations; litigation or regulatory proceedings involving us or our agents, including the outcome of ongoing investigations by several state governments, which could result in material settlements, fines or penalties, revocation of required licenses or registrations, terminations of contracts, other administrative actions or lawsuits and negative publicity; possible uncertainties relating to compliance with and the impact of the deferred prosecution agreement entered into with the U.S. federal government and the effect of the deferred prosecution agreement on our reputation and business; current or proposed regulations addressing consumer privacy and data use and security; our ability to successfully develop and timely introduce new and enhanced products and services and our investments in new products, services or infrastructure changes; our offering of money transfer services through agents in regions that are politically volatile or, in a limited number of cases, that are subject to certain Office of Foreign Assets Control restrictions; changes in tax laws or an unfavorable outcome with respect to the audit of our tax returns or tax positions, or a failure by us to establish adequate reserves for tax events; our substantial debt service obligations, significant debt covenant requirements and credit rating and our ability to maintain sufficient capital; our ability to manage risks associated with our international sales and operations; major bank failure or sustained financial market illiquidity, or illiquidity at our clearing, cash management and custodial financial institutions; the ability of us and our agents to maintain adequate banking relationships; a security or privacy breach in systems, networks or databases on which we rely; disruptions to our computer systems and data centers and our ability to effectively operate and adapt our technology; weakened consumer confidence in our business or money transfers generally; continued weakness in economic conditions, in both the U.S. and global markets; a significant change, material slow down or complete disruption of international migration patterns; the financial health of certain European countries, and the impact that those countries may have on the sustainability of the euro; our ability to manage credit risks from our retail agents and official check financial institution customers; our ability to retain partners to operate our official check and money order businesses; our ability to adequately protect our brand and intellectual property rights and to avoid infringing on the rights of others; our ability to attract and retain key employees; our ability to manage risks related to the operation of retail locations and the acquisition or start-up of businesses; any restructuring actions and cost reduction initiatives that we undertake may not deliver the expected results and these actions may adversely affect our business; our ability to maintain effective internal controls; our capital structure and the special voting rights provided to designees of Thomas H. Lee Partners, L.P. on our Board of Directors; and the risks and uncertainties described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of MoneyGram’s annual report on Form 10-K for the year ended December 31, 2014 and subsequent Forms 10-Q, as well as any additional risk factors that may be described in MoneyGram’s other filings with the Securities and Exchange Commission from time to time.

(CAMP) to Acquire (LOJN)

Combination Creates Leader in Connected Car Solutions and Vehicle Telematics Applications With More Than $400 Million in Annual Revenue Expected in Fiscal 2017 Expected to Be Accretive to CalAmp Non-GAAP Earnings per Share by $0.15 to $0.25 in First 12 Months Transaction Value of Approximately $134 Million

(AYA) Confirms Non-Binding Indication from CEO on All-Cash Acquisition

MONTREAL, Feb. 1, 2016  – Amaya Inc. (NASDAQ: AYA; TSX: AYA) confirmed today that it has received a non-binding indication from its Chairman and Chief Executive Officer, David Baazov, that he intends to make an all-cash proposal to acquire Amaya at a price currently estimated by Mr. Baazov to be C$21.00 per common share.   The board of directors of Amaya has established a special committee of independent directors to review any proposal that may be forthcoming, as well as other alternatives that may become available to Amaya.  Amaya’s Lead Independent Director, Dave Gadhia, will chair the special committee.

As of the time of this release, the special committee has neither received nor solicited a formal bid or offer related to a potential transaction and there can be no assurance that Mr. Baazov’s intention will result in a formal bid or offer or that any such bid or offer will ultimately result in a completed transaction.

Shareholders of Amaya do not need to take any action with respect to any potential proposal at this time. Amaya intends to provide updates if and when necessary in accordance with applicable securities laws.

About Amaya

Amaya is a leading provider of technology-based products and services in the global gaming and interactive entertainment industries. Amaya owns gaming and related consumer businesses and brands including PokerStars, Full Tilt, BetStars, StarsDraft, the European Poker Tour, PokerStars Caribbean Adventure, Latin American Poker Tour and the Asia Pacific Poker Tour. These brands have more than 97 million cumulative registered customers globally and collectively form the largest poker business in the world, comprising online poker games and tournaments, live poker competitions, branded poker rooms in popular casinos in major cities around the world, and poker programming created for television and online audiences. Amaya, through certain of these brands, also offers non-poker gaming products, including casino, sportsbook and daily fantasy sports. Amaya has various gaming and gaming-related licenses or approvals throughout the world, including from the United Kingdom, Italy, France, Spain, Estonia, Belgium, Denmark, Bulgaria, Greece, Ireland, Romania, the Isle of Man, Malta, the State of Schleswig-Holstein in Germany, the Province of Quebec in Canada, and the State of New Jersey in the United States.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable securities laws, including, without limitation, the intentions of Amaya’s Chief Executive Officer and certain potential future transactions. Forward-looking statements can, but may not always, be identified by the use of words such as “anticipate”, “propose”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “would”, “should”, “believe”, “objective”, “ongoing” and similar references to future periods or the negatives of these words and expressions. These statements, other than statements of historical fact, are based on management’s current expectations and are subject to a number of risks, uncertainties, and assumptions, including market and economic conditions, business prospects or opportunities, future plans and strategies, projections, technological developments, anticipated events and trends and regulatory changes that affect us, our customers and our industries. Although Amaya and management believe the expectations reflected in such forward-looking statements are reasonable and are based on reasonable assumptions and estimates, there can be no assurance that these assumptions or estimates are accurate or that any of these expectations will prove accurate. Forward-looking statements are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that could cause actual events to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include, but are not limited to, those identified under the heading “Risk Factors and Uncertainties” in Amaya’s Annual Information Form for the year ended December 31, 2014 and in its Management’s Discussion and Analysis for the period ended September 30, 2015, each available on SEDAR at www.sedar.com, EDGAR at www.sec.gov and Amaya’s website at www.amaya.com, and in other filings that Amaya has made and may make with applicable securities authorities in the future. Investors are cautioned not to put undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date hereof, and Amaya undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

(HNSN) Latest Publication in Journal of Interventional Cardiac Electrophysiology

Analysis of Catheter Contact Force During Atrial Fibrillation Ablation Using the Robotic Navigation System: Results From a Randomized Study

(CBMX) Study Published in Genetics in Medicine

Study Supports Follow-up Diagnostic Testing to Confirm Positive Results From Non-invasive Prenatal Testing

IRVINE, Calif., Feb. 01, 2016  — CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the publication of data from a CombiMatrix study supporting the value of follow-up diagnostic testing to either confirm or rule out positive results for common chromosomal aneuploidies and microdeletion syndromes detected by non-invasive prenatal testing (NIPT).

The data from the study appeared in the peer-reviewed Genetics in Medicine advance online publication (21 January 2016. doi:10.1038/gim.2015.196) submitted by Trilochan Sahoo, M.D., FACMG, CombiMatrix’s Vice President of Clinical Affairs and Director of Cytogenetics, in a letter to the editor entitled, “Expanding non-invasive prenatal testing to include microdeletions and segmental aneuploidy: cause for concern?” The letter provides “important and substantial addition” to the conclusion in a previously published article in Genetics in Medicine, “Maternal cell-free DNA-based screening for fetal microdeletion and the importance of careful diagnostic follow-up,” Yatsenko SA, et. al.

“Our study supports the need for extreme caution in the interpretation of NIPT due to higher-than-previously reported false positive rates compared with invasive testing and concern regarding the potential of over-representation of the positive predictive value for specific aneuploidies and microdeletions,” said Dr. Sahoo.  Common chromosomal fetal aneuploidies include Down (trisomy 21), Edwards (trisomy 18) and Patau (trisomy 13) syndromes, and common microdeletion syndromes are associated with conditions such as intellectual disability, seizures, autism spectrum disorder and neuropsychiatric disorder.

The CombiMatrix study included a review of the results of chromosomal microarrays and/or karyotype analysis following NIPT on 277 evaluable cases, showing a discordance rate of 20% and partial discordance rate of 11%.  The study included 25 cases in which NIPT showed a microdeletion or segmentation fetal aneuploidy.  The conclusion drawn in the Yatsenko, et. al, article was based on the observation of a single microdeletion case.

“The most significant and recent observation from our study showed a high rate of false positives for microdeletions,” continued Dr. Sahoo.  “This makes it extremely prudent to take a much more cautious approach to expanding NIPT for microdeletions with definitive testing such that we offer at CombiMatrix.”  Dr. Sahoo presented data from this study at the American Society of Human Genetics in October 2015.

“Major providers of NIPT are expanding beyond screening for common chromosomal fetal aneuploidies to common microdeletion syndrome and the results of these tests can lead to important decisions for women and their families,” said Mark McDonough, President and Chief Executive Officer of CombiMatrix.  “We recommend extensive pretest genetic counseling with a complete discussion of the benefits and limitations of screening versus diagnostic testing. This is particularly important for patients determined as low-risk for abnormalities in which abnormalities are detected with NIPT and for patients considered high-risk with normal NIPT results.”

Highlights of the 25 cases in which the CombiMatrix study compared NIPT results indicating aneuploidy and microdeletions with microarray and/or karyotyping results included:

• Discordance in 5 out of 7 cases with deletion 22q11.21; 5 out of 6 cases with deletion 5p; 3 out of 4 cases with deletion 1p36; and 1 out of 1 case with deletion 4p.
• Concordance in 1 case each identifying 15q deletion, a 9p duplication [confirmed to be an isodicentric (9p)] and a 13q deletion.
• Partial concordance in single cases as follows:
  • NIPT was suggestive of both 18p and 18q terminal deletions, diagnostic testing revealed only a deletion of 14 Mb at 18p11.32p11.21.
  • NIPT suggestive of trisomy 18q, diagnostic testing showed a duplication of 18p11.21q23 that was further characterized to be a translocation of the duplicated segment to the p-arm of one chromosome 13, resulting in trisomy for the 18p11.21q23 segment.
  • NIPT results indicated a “partial deletion of 21q,” diagnostic testing revealed a duplication of 9.2 Mb at 21q11.2-q21.1 that was inserted at 14p11.2.
• NIPT results were inconclusive for chromosome 13, microarray testing showed a large region of allelic homozygosity for chromosome 13.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in prenatal diagnostics, miscarriage analysis for recurrent pregnancy loss, pediatric genetics and pre-implantation genetic screening, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “goal,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding projected results of operations and management’s future business, operational and strategic plans, recruiting efforts and test menu expansion. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: whether follow-up diagnostic testing is more reliable than NIPT; whether the CombiMatrix study contains errors or could be contradicted or disproven by other studies; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests, develop and introduce new tests and related reports, expand and improve our current suite of services, optimize the reimbursements received for our microarray testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, steadily increase the size of our customer rosters in both prenatal and developmental genetic testing markets; our ability to attract and retain a qualified sales force in wider geographies; our ability to ramp production from our sales force and our strategic partners; rapid technological change in our markets; changes in demand for our future services; legislative, regulatory and competitive developments; the outcome of pending litigation; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624

Investor Relations Contact:
LHA
Jody Cain
(310) 691-7100
jcain@lhai.com

(OPCO) Commits to Further Innovation in Pet Products

New Partnership With Global Leader Aplix Underscores Strategic Commitment

(FDEF) Announces Share Repurchase Program

First Defiance Financial Corp. (NASDAQ: FDEF) announced today that its Board of Directors decided it is in the best interest of the Company and its shareholders to institute a new share repurchase program of up to 5%, or approximately 450,000 shares, of the common stock outstanding. Repurchases will be made periodically depending on market conditions and other factors. The repurchased shares will be held as treasury stock and will be available for general corporate purposes, including employee stock option plans. The exact number of shares to be repurchased by the company is not guaranteed.

Donald P. Hileman, President and Chief Executive Officer, said, “We believe that the repurchase of our stock is an important option within our overall capital management strategy. We completed the share repurchases under our previous authorization earlier this month and view this new authorization as an opportunity to continue offering additional value to our shareholders.”

Purchases under the First Defiance Financial Corp. stock repurchase program may be made periodically, in the open market, through block trades and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Commission or otherwise, and also in privately negotiated transactions. Depending on market conditions and other factors, these purchases may be commenced or suspended at any time or periodically without prior notice. As of January 28, 2016, First Defiance Financial Corp. had 9,009,674 shares outstanding.

First Defiance Financial Corp.

First Defiance Financial Corp., headquartered in Defiance, Ohio, is the holding company for First Federal Bank of the Midwest and First Insurance Group. First Federal operates 34 full-service branches and 41 ATM locations in northwest Ohio, southeast Michigan and northeast Indiana and a loan production office in Columbus, Ohio. First Insurance Group is a full-service insurance agency with six offices throughout northwest Ohio.

For more information, visit the company’s Web site at www.fdef.com.

Safe Harbor Statement

This news release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 B of the Securities Act of 1934, as amended, which are intended to be safe harbors created thereby. Those statements may include, but are not limited to, all statements regarding intent, beliefs, expectations, projections, forecasts and plans of First Defiance Financial Corp. and its management, and specifically include statements regarding: changes in economic conditions, the nature, extent and timing of governmental actions and reforms, future movements of interest rates, the production levels of mortgage loan generation, the ability to continue to grow loans and deposits, the ability to benefit from a changing interest rate environment, the ability to sustain credit quality ratios at current or improved levels, the ability to sell real estate owned properties, continued strength in the market area for First Federal Bank of the Midwest, and the ability to grow in existing and adjacent markets. These forward-looking statements involve numerous risks and uncertainties, including those inherent in general and local banking, insurance and mortgage conditions, competitive factors specific to markets in which First Defiance and its subsidiaries operate, future interest rate levels, legislative and regulatory decisions or capital market conditions and other risks and uncertainties detailed from time to time in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the year ended December 31, 2014. One or more of these factors have affected or could in the future affect First Defiance’s business and financial results in future periods and could cause actual results to differ materially from plans and projections. Therefore, there can be no assurances that the forward-looking statements included in this news release will prove to be accurate. In light of the significant uncertainties in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by First Defiance or any other persons, that our objectives and plans will be achieved. All forward-looking statements made in this news release are based on information presently available to the management of First Defiance. We assume no obligation to update any forward-looking statements.

As required by U.S. GAAP, First Defiance will evaluate the impact of subsequent events through the issuance date of its December 31, 2015 consolidated financial statements as part of its Annual Report on Form 10-K to be filed with the SEC. Accordingly, subsequent events could occur that may cause First Defiance to update its critical accounting estimates and to revise its financial information from that which is contained in this news release.

First Defiance Financial Corp.
Donald P. Hileman, President and CEO, 419-782-5104
dhileman@first-fed.com

(CCRN) CFO William Burns Receives South Florida Business Journal Award

The South Florida Business Journal (SFBJ) recognized Cross Country Healthcare’s Chief Financial Officer William Burns with its annual “Turnaround Achievement of the Year” award during their 9^th Annual CFO Awards on Thursday, January 28, 2016.

Cross Country Healthcare President and Chief Executive Officer William Grubbs said, “I am pleased to announce that our company was honored with this prestigious award. 2015 was a year of strong revenue growth and significantly improved profitability thanks to the efforts, energy, resilience and commitment of our CFO, Bill Burns, and all of our employees.”

The SFBJ hosts the annual event to shine a spotlight on the growing importance of financial executives in the economic community. The award recognizes a CFO for strategic brilliance in leading their organization to outstanding growth and was determined by the South Florida Business Journal Editorial Team and a panelist of industry experts. This year’s event, presented by Steven Douglas Associates, took place on Thursday, January 28, 2016 at the Hyatt Regency Pier 66 on the 17^th Street Causeway in Fort Lauderdale.

About Cross Country Healthcare

Cross Country Healthcare, headquartered in Boca Raton, Florida, is a national leader in providing leading-edge healthcare workforce solutions. Our solutions are geared towards assisting our clients to solve labor cost issues while maintaining high quality outcomes. With more than 30 years of experience, we are dedicated to placing highly qualified nurses and physicians as well as allied health, advanced practice, and case management professionals. We also provide both retained and contingent placement services for physicians, as well as retained search services for healthcare executives. We have more than 6,500 active contracts with a broad range of clients in both clinical and nonclinical settings, including acute care hospitals, physician practice groups, nursing facilities, both public schools and charter schools, rehabilitation and sports medicine clinics, government facilities, and homecare. Through our national staffing teams and network of more than 70 branch office locations, we are able to place clinicians for travel and per diem assignments, local short-term contracts and permanent positions. We are a market leader in providing flexible workforce management solutions, including managed services programs (MSP), electronic medical record (EMR) transition staffing, recruitment process outsourcing, predictive analytics, education healthcare staffing solutions, internal resource pool consulting and development, and other consultative services.

Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com.

(CHLN) Announces Date For Proposed Reverse Stock Split

XI’AN, China, Jan. 29, 2016  — China Housing & Land Development, Inc. (NASDAQ: CHLN) (the “Company”) announced today that the Company’s board of directors (the “Board”) set record and effective dates for the previously announced 1-for-50,000 reverse stock split of the Company’s common stock (the “Reverse Stock Split”).  At a meeting held on January 28, 2016 Beijing time the Board unanimously approved a record date of February 15, 2016 and an effective date of February 18, 2016 for the Reverse Stock Split.

As described in the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on December 31, 2015, the Company’s stockholders approved the Reverse Stock Split at a special meeting of the Company’s stockholders held on December 30, 2015 Beijing time (December 29, 2015 U.S. Eastern Time).   Implementation of the Reverse Stock Split is expected to reduce the number of the Company’s stockholders of record to less than 300 and allow the Company to “go private” by terminating its registration under the Securities Exchange Act of 1934 and removing its common stock from quotation on the NASDAQ.

About China Housing & Land Development, Inc.
Based in Xi’an, the capital city of China’s Shaanxi province, China Housing & Land Development, Inc. is a leading developer of residential and commercial properties in northwest China and the first Chinese real estate development company traded on NASDAQ.  China Housing has been engaged in land acquisition, development, and management, including the sales of residential and commercial real estate properties through its wholly-owned subsidiary in China, since 1992.

Safe Harbor
Certain statements herein that reflect management’s expectations regarding future events are forward-looking in nature and, accordingly, are subject to risks and uncertainties, which is covered under the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995.  Such statements include, among others, all assumptions, expectations, predictions, intentions or beliefs about future events.  Forward-looking statements can be identified by the use of forward-looking terminology such as “will,” “believes,” “expects” or similar expressions.  Such information is based upon expectations of our management that were reasonable when made but may prove to be incorrect.  All of such assumptions are inherently subject to uncertainties and contingencies beyond our control and based upon premises with respect to future business decisions, which are subject to change.  We do not undertake to update the forward-looking statements contained in this press release.  Among others, the following risks, uncertainties and other factors could cause actual results to differ from those set forth in the forward-looking statements: the risk that the Transaction may be delayed or may not be consummated; risks related to the diversion of management’s attention from our ongoing business operations; the effect of the announcement of the proposed Transaction or operational activities taken in anticipation of the Transaction on our business relationships, operating results and business generally; the outcome of any legal proceedings that have been or may be instituted against us related to the Transaction; and the amount of the costs, fees, expenses and charges related to the Transaction.  For a description of additional risks and uncertainties that may cause actual results to differ from the forward-looking statements contained in this press release, see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), and our subsequent SEC filings.  Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis retrieval system at http://www.sec.gov.

For additional information please contact:
Ms. Jing Lu, Chief Operating Officer, Director, and Investor Relations Officer
+86 29.8258.2639 (Email: jinglu@chldinc.com)

Mr. Qingwei Liu
+86 29.8332.8813 (Email: liuqw@chldinc.com)

(UHAL) U.S. Growth City No. 6: College Station, Texas A&M are Popular Choices

Incoming Trucks Account for 53.7 Percent of U-Haul Traffic in Aggieland

COLLEGE STATION, Texas, Jan. 29, 2016  — The official “Home of the 12th Man” is home to a lot of U-Haul do-it-yourself movers.

College Station made the U-Haul Top 10 U.S. Growth Cities for 2015 at No. 6. Growth rankings are determined by the net gain of incoming one-way U-Haul truck rentals versus outgoing rentals for the past calendar year.

Read the entire College Station release, including additional quotes, facts, statistics, infographics and photos at myuhaulstory.com.

U-Haul locations in College Station saw 53.7 percent of truck rental customers coming into the city as opposed leaving, and welcomed 1 percent more U-Haul arrivals and departures year-over-year.

Texas A&M University is the city’s largest employer and centerpiece of the Bryan-College Station metro area with an enrollment of nearly 60,000 students.

“A&M continues to grow, and College Station is seeing a lot of growth in apartment and retail buildings – retail on the first floors and housing above,” said Matt Merrill, president of U-Haul Company of West Houston. “The overall business market continues to grow for U-Haul there.”

The housing and jobs sectors have been on the upswing in College Station, according to multiple reports, adding appeal to the area at a time when other Texas cities have been hurt by the slumping oil sector.

Texas A&M’s 2012 move to the Southeastern Conference only helped College Station and the Aggies’ sports profile, which translated to a massive football stadium expansion project. And based on the U-Haul trucks pulling into town, there should be plenty of people to fill those seats.

“The community is close-knit and the city is very well managed, very clean and very well kept,” Merrill said. “The crime rate is very low. It’s a very friendly place even though it continues to grow. Everybody comes in and says hello – and they’re darn sure not Yankees.”

While U-Haul migration trends don’t correlate directly to population or economic growth, the growth cities data is a strong gauge of how well cities are attracting and keeping residents. The report was compiled from more than 1.7 million one-way U-Haul truck transactions that occurred in 2015. All cities were considered, regardless of size.

Discover the U-Haul Top 10 U.S. Growth Cities named so far and continue following the countdown at myuhaulstory.com and via Twitter @uhaul.

Contact

Jeff Lockridge
Sebastien Reyes
E-mail: publicrelations@uhaul.com
Phone: 602-263-6194
Website: uhaul.com

(XENT) Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany

Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that InEk, the German Institute for the Hospital Remuneration System, has assigned NUB (Neue Untersuchungs und Behandlungsmethoden) Status 1 for mometasone furoate implants for 2016.

The purpose of the NUB process is to support the initial introduction of new and innovative medical products by allowing a limited number of participating hospitals to receive reimbursement. NUB Status 1 is the highest priority designation available, and was only assigned to a minority of product submissions for 2016.

“We believe that the robust clinical evidence supporting PROPEL was key to this favorable decision, which we received on the first application round,” stated Lisa Earnhardt, president and chief executive officer, Intersect ENT. “While our focus as a company is very much on U.S. commercialization as well as development of our pipeline products, this represents an important step in our efforts to build a foundation for international expansion over the coming years.”

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.

Forward-Looking Statements

The statements in this press release regarding the ability of hospitals to negotiate for additional funding to cover the cost of procedures and Intersect ENT’s ability to expand its business internationally are “forward-looking” statements. These forward-looking statements are based on Intersect ENT’s current expectations and inherently involve significant risks and uncertainties. These statements include those related to the review of data by and timing for approval by the FDA as well as the rate of patient adoption for Intersect ENT’s products, if approved. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, the performance of PROPEL and PROPEL mini, the development of competitive products, the uncertain timing of completion of and the success of clinical trials and market competition. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Intersect ENT’s filings on Form 10-K, Form 10-Q and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

XENT-G

View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005281/en/

(MCRB) Announces Participation at Two Upcoming Investor Conferences

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will participate in two investor conferences in February:

• Canaccord Genuity Rare Disease, BioPharma One-on-One Day on Tuesday, Feb. 2, 2016 in New York, NY.
• Leerink Partners Global Healthcare Conference on Feb. 10 – 11, 2016 in New York, NY.

Roger Pomerantz, M.D., Chairman, President and CEO of Seres, will participate in a question and answer session on the first day of the Leerink Partners Global Healthcare Conference. The session will be available under the Investors and Media section of Seres’ website at www.serestherapeutics.com. A replay of the session will become available approximately one hour after the event and will be archived on the site for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres’ most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring Clostridium difficile infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres’ second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).

IR Contact:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com
or
PR Contact:
Ten Bridge Communications
Dan Quinn, 781-475-7974
Dan@tenbridgecommunications.com

(TRXC) to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

TransEnterix, Inc. (NYSE MKT: TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the LEERINK Partners 5^th Annual Global Healthcare Conference at the Waldorf Astoria Hotel in New York. The presentation is scheduled to take place at 3:05 pm Eastern Time on Thursday, February 11, 2016.

To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm. The replay will be available on the company’s website.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X®, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not yet available for sale in any market. The ALF-X has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at www.transenterix.com.

TransEnterix, Inc.
Investor Contact:
Mark Klausner, 443-213-0501
transenterix@westwicke.com
or
Media Contact:
Mohan Nathan, 919-917-6559
mnathan@transenterix.com

(CBMG) Announces Chairman of Board, CEO Appointment

SHANGHAI, China and CUPERTINO, Calif., Jan. 28, 2016  — Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced the election of Terry A. Belmont as Chairman of the Board of Directors, and the appointment of Tony (Bizuo) Liu to Chief Executive Officer, effective February 7, 2016.

The Board of Directors of CBMG issued the following statement: “We are delighted that Terry Belmont, a well-respected and seasoned healthcare veteran, will be leading CBMG’s strategic growth efforts as independent Chairman of the Board of Directors. Having recently retired as CEO of University of California, Irvine Health, Mr. Belmont brings an extensive array of experience in large-scale health sector institutions along with vast corporate and community Board experience, all of which will continue to serve CBMG well. The Board expresses its sincere appreciation for the tireless efforts of outgoing Chairman, Wentao (Steve) Liu for his guidance and leadership, and are grateful for his business experience as he continues to serve as a Director and strategic advisor to CBMG’s management team.”

The Board also confirmed the appointment of Tony (Bizuo) Liu, currently Chief Financial Officer, to the position of Chief Executive Officer. “The depth and breadth of Tony’s multinational strategic planning, finance and investment experience combined with his tenure at CBMG will be a tremendous asset in leading CBMG through its next phase of growth and success,” commented Chairman Terry Belmont. “I am confident that Tony will excel in his new role as the company continues to fortify its technology platforms and enlarge its development pipelines.”

Tony Liu commented, “Biotechnology, analogous to the technology companies I have led, is prime for innovation and disruption and I look forward to leading the development of CBMG’s immuno-oncology and stem cell research programs and driving clinical patient benefits in these exciting fields. CBMG is well on its way to being a leader in this domain as we strategically position the Company to monetize our growing cellular therapy programs, deliver value to our stakeholders and serve large patient populations under a world-class infrastructure. I’m pleased to lead the Company through this important stage of growth and success.”

Tony Liu will continue to serve as the Company’s Chief Financial Officer while an executive search for a successor is underway.

About Terry A. Belmont 
Mr. Belmont has been serving CBMG as an Independent Director since December 2013 and as Vice Chairman of the Board since March 2015.

Mr. Belmont has over 35 years of experience in leading major medical centers and healthcare entities with multi-campus responsibilities.  Before he retired from his CEO position at University of California, Irvine Health in June 2015, Mr. Belmont had lead the transition of this medical center into a leading regional and nationally recognized healthcare system. Among his notable accomplishments at UC Irvine Health, Mr. Belmont added the state of the art Douglas Hospital as part of UC Irvine Medical Center, a 7 story clinical laboratory building, the establishment or outpatient centers throughout the Orange County Region, the development of affiliated healthcare networks to serve the entire region and, most importantly, partnered with the leadership of the School of Medicine in significantly improving the medical center’s quality of care reputation throughout the United States.

From 2006 to 2009 Mr. Belmont served as CEO of Long Beach Memorial Medical Center and Miller Children’s Hospital. He has also served as president and chief executive officer in St. Joseph Hospital of Orange, Pacific Health Resources, California Hospital Medical Center and HealthForward.  He continues to participate in several healthcare organizations in improving continuity of care in various California communities.

Mr. Belmont’s community involvement has included board positions with the March of Dimes, Orange County World Affairs Council, Southern California College of Optometry, American Heart Association and Children’s Fund. He also serves on the Board of Trustees of the University of Redlands. He was also a founding board member of Pacificare Health Systems, which was acquired by United Healthcare in early 2000.  Mr. Belmont received his master’s in public health with a major in hospital administration from UC Berkeley, and a bachelor’s in business from the University of Redlands.

About Tony (Bizuo) Liu
Mr. Liu began serving CBMG as an Independent Director and Chairman of the Audit Committee in March 2013, after which he was appointed as Chief Financial Officer in January 2014.

Previously, Mr. Liu served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, he held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global ecommerce platform.  He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider. Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles.  He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process.  Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director.  He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S.  Tony obtained his Washington State CPA certificate in 1992.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases.  Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our GMP facilities in China, consisting of nine independent cell production lines, are designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contacts:
Sarah Kelly 
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com

Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com

(STRS) Carl E. Berg Announces Receipt Of Unsolicited Portfolio Offer

CUPERTINO, Calif., Jan. 28, 2016  — Carl E. Berg, the largest shareholder (17.6%) of Stratus Properties Inc. (Nasdaq: STRS), today announced that on January 25, 2016, he received from Capretta Properties Inc. a copy of Capretta’s January 22 letter of intent to Stratus offering to purchase substantially all of Stratus’s real estate properties for $435 million cash.  The terms of the offer provide for the properties to be transferred to Capretta free of existing debt, which Capretta noted in the letter aggregated approximately $255.6 million on September 30, 2015.  Capretta’s nine-page letter of intent was addressed to William Armstrong, Stratus’ CEO, and indicates that Capretta sent copies of the letter to Stratus’ five largest stockholders, including Mr. Berg.  The letter describes Capretta’s offer as representing “an offer equal to $21.60 per share net of existing debt” for Stratus’s real estate portfolio alone.  Capretta also notes in the letter that Stratus has “other assets, including cash, that total over $6.00 per share” and, as a result, Capretta’s offer “presents a financial return to Stratus far in excess of its current stock price in the $19.00 range.”  Mr. Berg understands that statement to mean that Capretta’s offer implies a liquidation value of Stratus of approximately $27.60 per share (pretax). Capretta’s offer states that it is not subject to any financing contingency and that no real estate brokerage commissions will be payable by either party.

Capretta Properties is a privately owned real estate development and investment company that was established in 1989 and is based in Mill Valley, California.

Mr. Berg said: “After having submitted for a vote at the 2016 Annual Meeting a proposal requesting Stratus’ Board of Directors to engage an investment banker to explore a sale of Stratus, I am delighted to learn that four months before the expected date of that annual meeting Stratus has received an unsolicited offer from a credible party to purchase all of Stratus’ real estate assets. To me, Capretta’s offer appears to have significant merit and represents an excellent point from which to begin the process of exploring the sale of Stratus.  I definitely agree that Stratus should not incur any brokerage fees in connection with selling its real estate portfolio in response to a third party’s unsolicited offer to purchase Stratus’ real estate assets.  After the Stratus shareholders have endured years of underperformance by Stratus, the Board – including its two recent Board appointees, James Joseph and John Wenker – needs to seriously and objectively evaluate Capretta’s offer and any other offers that Stratus receives, with the aim of allowing Stratus’ stockholders to realize the full value of Stratus’ real estate portfolio.  I repeat what I wrote on December 19, 2015 to each Board member:  I will hold them accountable for any lack of independence, unsound business decisions or failure to live up to their legal obligations to the Stratus shareholders. I am making today’s announcement because all of the shareholders deserve to know that Stratus has received this significant offer, but Stratus has made no public statement to its owners about the offer.”

Capretta’s president, Ricardo Capretta, addressed the letter of intent to Stratus’s Chairman and CEO William Armstrong, and begins the letter by stating:  “I have tried to contact you on five separate occasions now [December 12 and 18, 2015; January 4, 19 and 20 of 2016].  I appreciate that you returned one of my calls on January 19….  I have not received a second return phone call….  At this point, it does not seem as though I will hear back from you so therefore I thought it might be more productive to forward you an unsolicited offer for your assets since they are possibly going to be offered for sale soon.  I understand that potential suitors have, or are considering submitting unsolicited offers, in the near future.”

Stratus is a real estate company engaged primarily in the development, management, operation and sale of commercial, hotel, entertainment, and multi- and single-family residential real estate properties located in Texas, primarily in the Austin, Texas area.

Mr. Berg is a real estate investor and venture capitalist and was the Chief Executive Officer of Mission West Properties, a real estate investment trust, from 1997 through December 22, 2012, when that company was sold to DivcoWest, a privately owned real estate investment company.  He believes he has been Stratus’ largest shareholder for almost the last 15 years.

Contact:
Carl E. Berg
10050 Bandley Drive
Cupertino, California 95014
(408) 725-0700

(BBEPP) Partners Declares Monthly Distributions for Preferred Units

Breitburn Energy Partners LP (NASDAQ:BBEP) announced today distributions for its 8.25% Series A Cumulative Redeemable Perpetual Preferred Units (NASDAQ: BBEPP) and 8% Series B Perpetual Convertible Preferred Units. A cash distribution of $0.171875 per Series A Unit is payable on March 15, 2016, to record holders of its Series A Units at the close of business on February 29, 2016. This monthly distribution is equal to an annual distribution of $2.0625 per Series A Unit. Breitburn has elected to pay the distribution on its Series B Units in kind by issuing additional Series B Units instead of paying a cash distribution. A distribution of 0.006666 PIK unit per Series B Unit is payable on February 15, 2016, to record holders of Series B Units at the close of business on January 29, 2016.

About Breitburn Energy Partners LP

Breitburn Energy Partners LP is a publicly traded, independent oil and gas master limited partnership focused on the acquisition, development, and production of oil and gas properties throughout the United States. Breitburn’s producing and non-producing crude oil and natural gas reserves are located in the following seven producing areas: Ark-La-Tex, Michigan/Indiana/Kentucky, the Permian Basin, Mid-Continent, the Rockies, Florida, and California. See www.breitburn.com for more information.

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Breitburn expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by Breitburn based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict, including those which are set forth under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, and if applicable, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.

Non-U.S. investors are not eligible holders of Breitburn common, Series A Units, and Series B Units. This press release is intended to provide a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100.0%) of Breitburn’s distributions to non-U.S. investors as being attributable to income that is effectively connected with a U.S. trade or business. Accordingly, Breitburn’s distributions to non-U.S. investors are subject to federal income tax withholding at the highest applicable effective tax rate.

BBEP-IR

Breitburn Energy Partners LP
Antonio D’Amico
Vice President, Investor Relations & Government Affairs
or
Jessica Tang
Investor Relations Manager
(213) 225-0390

(CIFC) Engages JPMorgan to Assist in Exploration of Strategic Alternatives

NEW YORK, Jan. 28, 2016  — CIFC LLC (NASDAQ:CIFC) and its subsidiaries (collectively “CIFC” or the “Company”) announced the engagement of JPMorgan Securities LLC to assist the Company and management in exploring a range of strategic alternatives to enhance shareholder value and to capitalize on its industry-leading platform.  Those alternatives may include a sale of the Company or the sale of a stake in the Company to a strategic investor with the objective of accelerating the Company’s existing growth and diversification initiatives.

The Company has not made a decision to enter into any transaction at this time and there can be no assurance that exploration of its strategic alternatives will result in a transaction and there is no set timetable for actions to be taken in the process.  The Company does not intend to discuss or disclose any developments related to the process until the Board has approved a definitive course of action or otherwise concludes the process.

About CIFC
Founded in 2005, CIFC is a private debt manager specializing in secured U.S. corporate loan strategies with approximately $14.2 billion of assets under management as of September 30, 2015. Headquartered in New York, CIFC is an SEC registered investment adviser and is listed on NASDAQ. The firm currently serves more than 200 institutional investors globally. For more information, please visit CIFC’s website at www.cifc.com.

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements regarding future results or expectations. Forward-looking statements can be identified by forward-looking language, including words such as “believes,” “anticipates,” “expects,” “estimates,” “intends,” “may,” “plans,” “projects,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made, various operating assumptions and predictions as to future facts and conditions, which may be difficult to accurately make and involve the assessment of events beyond CIFC’s control. Caution must be exercised in relying on forward-looking statements. The forward-looking statements in this release are subject to risks and uncertainties, and the other risks related to CIFC’s business that are described in its annual report on Form 10-K. The forward-looking statements contained in this press release are made as of the date hereof, and CIFC undertakes no obligation to update any forward-looking statement to reflect subsequent events, new information or circumstances arising after the date hereof.

CONTACT: Investor Relations at InvestorRelations@cifc.com or +1 (212)-624-4508

(AMDA) to Present Research Supporting Favorable Silicon Nitride Findings

Four Scientific Presentations Demonstrate Superiority of Silicon Nitride Over Existing Biomaterials

SALT LAKE CITY, Jan. 28, 2016  — Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce all four submissions to the Orthopaedic Research Society (“ORS”) Annual Meeting were accepted for presentation occurring March 5-8, 2016 in Orlando, Florida.

“Our presentations will demonstrate the rationale for using our proprietary silicon nitride composition in a variety of medical applications within the $15 billion surgical spine, dental, hip and knee replacement markets,” said Dr. Sonny Bal, Chairman and CEO of Amedica Corporation. “This scientific data will convincingly demonstrate the serious limitations of other existing biomaterials, while highlighting the advantages of silicon nitride, even as we continue further testing on an improved second generation silicon nitride composition. I’m very proud of our continued innovation and robust science, which will be presented at this important orthopedic forum.”

Accepted submission titles and their authors include:

• Metal Ions Contribute to the Material Instability of Zirconia Toughened Alumina – Giuseppe Pezzotti, Leonardo Puppulin, Marco Boffelli, Nobuhiko Sugano, Bryan J. McEntire (Presenter), and B. Sonny Bal
• Differential Bacterial Expression on Silicon Nitride, PEEK, and Titanium Surfaces – Bryan J. McEntire (Presenter), Erin N. Jones, Darin Ray, Ryan M. Bock, B.Sonny Bal, and Giuseppe Pezzotti
• Do Ceramic Femoral Heads Contribute to Polyethylene Oxidation? – Bryan J. McEntire (Presenter), Yuto Enomoto, Wenliang Zhu, Marco Boffelli, Elia Marin, B. Sonny Bal, and Giuseppe Pezzotti
• Differential Effects of Hydrothermal Ageing on the Surface Fracture Toughness of Ceramics – Bryan J. McEntire (Presenter), Erin N. Jones, Darin Ray, Ryan M. Bock, B.Sonny Bal, and Giuseppe Pezzotti

The ORS annual meeting attracts attendees from all over the world—clinicians, surgeons, residents, veterinarians, basic scientists, and engineers who come together to present the latest innovative and cutting-edge musculoskeletal research.

About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

About Orthopaedic Research Society
Orthopaedic Research Society (ORS) exists to promote, support, develop and encourage research in surgery and musculoskeletal disease and disciplines. Every year, the ORS meeting attracts over 3,000 attendees with an interest in orthopaedic research including clinicians, surgeons, residents, veterinarians, basic scientists, and engineers.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica’s future performance, business operations and acceptance of its technology platform. Statements relating to Amedica’s market opportunities, growth, future products, market acceptance of its products, sales and financial results and similar statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica’s products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts:
Mike Houston
VP, Commercialization
801-839-3534
IR@amedica.com

Robert Haag
IRTH Communications
866-976-4784
amda@irthcommunications.com

(MRCY) to Present at Cowen & Company 37th Annual Aerospace/Defense Conference

CHELMSFORD, Mass., Jan. 27, 2016  — Mercury Systems, Inc. (NASDAQ:MRCY) (www.mrcy.com), announced that it will participate in the Cowen and Company 37th Annual Aerospace/Defense Conference to be held February 3-4, 2016, at the Lotte New York Palace Hotel in New York City. Management will present an overview of the Company’s business Wednesday, February 3^rd, at 10:30 a.m. ET.

The presentation will be webcast live and may be accessed from the investor section of Mercury’s website at http://ir.mrcy.com/events.cfm. A replay of the webcast will be available for 90 days.

Mercury Systems – Innovation That Matters^™

Mercury Systems (NASDAQ:MRCY) is the better alternative for affordable, secure and sensor processing subsystems designed and made in the USA. Optimized for program and mission success, Mercury’s solutions power a wide variety of critical defense and intelligence applications on more than 300 programs such as Aegis, Patriot, SEWIP, F-35 and Gorgon Stare. Headquartered in Chelmsford, Massachusetts, Mercury Systems is a high-tech commercial company purpose-built to meet rapidly evolving next-generation defense electronics challenges. To learn more, visit www.mrcy.com.

Mercury Systems and Innovation That Matters are trademarks of Mercury Systems, Inc.

Contact:
Gerry Haines, CFO
Mercury Systems, Inc.
978-967-1990

(ALQA) Announces Agreement With HealthTrust

LANGHORNE, Pa., Jan. 27, 2016  — Alliqua BioMedical, Inc. (Nasdaq:ALQA) (“Alliqua” or “the Company”), a provider of advanced wound care products, today announces that it has signed a national group purchasing agreement with HealthTrust. The agreement, which became effective on Jan. 1, 2016, added Alliqua’s Biovance® Human Amniotic Membrane Allograft (“Biovance”) to HealthTrust’s regenerative tissue wound care contracting category.

Biovance is intended for use as a biological membrane covering applied in the treatment of a wide range of wounds and in surgical procedures. Common uses are on partial- and full-thickness acute and chronic wounds and, in surgery, to protect the underlying tissue and preserve tissue plane boundaries with minimized adhesion or scar formation.

“We are pleased to be selected as a HealthTrust supplier as we work toward increasing access in the marketplace to all of our wound care technologies,” said Brad Barton, Chief Operating Officer of Alliqua BioMedical.

About Alliqua BioMedical, Inc.

Alliqua is a provider of advanced wound care solutions, committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner’s ability to deal with the challenges of healing both chronic and acute wounds.

Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet S® and sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. The Company’s Mist Therapy System® uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets the human biologic wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.

In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. Alliqua’s electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua’s hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. The Company has locations in Langhorne, PA and Eden Prairie, MN.

For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.

About HealthTrust

HealthTrust (legally known as Healthtrust Purchasing Group, L.P.) is committed to strengthening provider performance and clinical excellence through an aligned membership model and the delivery of total cost management solutions, including supply chain solutions and a contract and service portfolio unparalleled in quality, scope and value. HealthTrust (www.healthtrustpg.com) serves over 1,400 acute care facilities and members in more than 22,300 other locations, including ambulatory surgery centers, physician practices, long-term care and alternate care sites. Headquartered in Brentwood, Tennessee, HealthTrust is an affiliate of Parallon Business Solutions, LLC (www.parallon.com), a leading provider of healthcare business and operational services, including revenue cycle management, workforce and technology solutions. On Twitter @healthtrustpg and @parallonconnect.

Legal Notice Regarding Forward-Looking Statements:

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses;  price increases for supplies and components; and the inability to carry out research, development and commercialization plans.  In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com

(NLST) Federal Circuit Denies Inphi Rehearing On LRDIMM Patent Case

Supreme Court appeal now only recourse to challenge 60 claims covering the operation of LRDIMM

IRVINE,Calif., Jan. 27, 2016  — Netlist, Inc. (NASDAQ: NLST), announced today that the U.S. Court of Appeals for the Federal Circuit has denied Inphi’s petition for a rehearing of its November 2015 precedential opinion which had affirmed the validity of  U.S. Pat. No. 7,532,537 (“‘537 Patent”).

This final decision by the Federal Circuit is a landmark victory for Netlist’s ‘537 patent after more than four years of scrutiny in the US Patent and Trademark Office and one year of appeals in the federal court system. In order to continue to challenge the validity of this patent, Inphi must now appeal directly to the U.S. Supreme Court.

“The denial of Inphi’s petition for rehearing is for all practical purposes, the final step in the complete validation of the ‘537, one of Netlist’s seminal LRDIMM patents,” said Netlist’s Chief Executive Officer, C.K. Hong.  “With more than thirty U.S. and foreign patents broadly covering fundamental aspects of LRDIMM, this final decision by the Federal Circuit puts us in the strongest possible position to pursue licensing opportunities in the fast growing LRDIMM market.”

According to De Dios & Associates, the LRDIMM market was estimated to be $3 billion in 2015 and is projected to reach around $7 billion by 2018.

About Netlist, Inc.
Netlist creates solutions that accelerate turning data into information. We design and manufacture controller and software-based memory solutions for our OEM and Hyperscale customers in the server and storage space. Flagship products NVvault® and EXPRESSvault™ accelerate system performance and provide mission critical fault tolerance. HyperVault®, Netlist’s next-generation architecture, expands the performance and capacity of memory channel storage. The company holds a portfolio of patents, many seminal, in the area of hybrid memory, rank multiplication and load-reduction, among others. To learn more, visit www.netlist.com.

Safe Harbor Statement:
This news release contains forward-looking statements regarding future events and the future performance of Netlist. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expected or projected. These risks and uncertainties include, but are not limited to, our ability to regain compliance with NASDAQ listing rules, risks associated with the launch and commercial success of our products, programs and technologies; our capital resources; the success of product partnerships; continuing development, qualification and volume production of HyperVault™, EXPRESSvault™, NVvault®, HyperCloud^® and VLP Planar-X RDIMM; the timing and magnitude of the decrease in sales; our ability to leverage our NVvault® and EXPRESSvault™ technology in a more diverse customer base; the rapidly-changing nature of technology; risks associated with intellectual property, including risks associated with the inherent uncertainty of the litigation process; patent infringement litigation against us as well as the costs and unpredictability of litigation over infringement of our intellectual property and the possibility of our patents being reexamined by the United States Patent and Trademark office; volatility in the pricing of DRAM ICs and NAND; changes in and uncertainty of customer acceptance of, and demand for, our existing products and products under development, including uncertainty of and/or delays in product orders and product qualifications; delays in the Company’s and its customers’ product releases and development; introductions of new products by competitors; changes in end-user demand for technology solutions; the Company’s ability to attract and retain skilled personnel; the Company’s reliance on suppliers of critical components and vendors in the supply chain; fluctuations in the market price of critical components; evolving industry standards; and the political and regulatory environment in the People’s Republic of China. Other risks and uncertainties are described in the Company’s annual report on Form 10-K filed on March 27, 2015, and subsequent filings with the U.S. Securities and Exchange Commission made by the Company from time to time. Except as required by law, Netlist undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(SBSA) Calibash 2016 Raises Bar As Most Successful Urban Music Concert in LA

LOS ANGELES, Jan. 27, 2016  — Spanish Broadcasting System, Inc. (SBS) (NASDAQ: SBSA), the favorite station of millennial youth in Los Angeles, MEGA 96.3FM successfully hosted Calibash 2016, the most anticipated urban and rhythmic music concert in Los Angeles featuring world renowned artists Snoop Dogg and Lil Jon as well as the hottest Latin music singers today including J Balvin, Prince Royce, Nicky Jam, Plan B, Yandel, Farruko, Becky G, J Alvarez, Justin Quiles, Zion & Lennox and Henry Santos. The sold-out Calibash 2016, hosted by KXOL Mega 96.3FM, LaMusica and produced by AEG Live and Latin Events took place on Sunday, January 24, 2016 at STAPLES Center in Los Angeles, California.

As one of the most important and climaxing moments of the night, J Balvin invited Justin Bieber to the stage to perform the remix of the hit song “Sorry.” Lil Jon, Becky G and Yandel also performed for the first time their upcoming single “Take It Off.”  Calibash continues to be the perfect platform for showcasing upcoming music hits and new artists’ collaborations given the massive media coverage and social media interaction the event enjoys. But the stars were not only onstage, celebrities such as Floyd Mayweather, Larry Hernandez, Yasiel Puig, Jonathan Sanchez, Adriel Favela, Martin Castillo, Kurupt were seen in attendance.

During CALIBASH 2016, SBS revealed the LaMusica app logo above the stage. LaMusica is the company’s mobile music product that offers exclusive content including live streams of SBS’ market-leading radio stations and talent, a “My Radio” innovative personalization tool, hundreds of expertly curated playlists as well as social networking features and access to more than 23 million songs. The app is available for free download at the Apple store and Google Play.

“I’m so proud of SBS LA’s team effort and positive contributions; #CALIBASH2016 broke attendance records, revenue records and showcased the most popular current Latin and English artists. Mega 96.3FM signature event CALIBASH entertained the Los Angeles millennials through mobile, digital and social media making the event a top trending topic across various platforms,” stated Marko Radlovic, Senior Vice President and West Coast Regional Manager at Spanish Broadcasting System.

“Music festivals and concerts come and go but very few grow into a reputable brand as Calibash has. With a sold-out concert, Mega 96.3FM once again has proven to enjoy the loyal following of bilingual and bicultural millennials and provides them a top of the line event that features the most popular English and Spanish language music singers preferred by this coveted consumer group,” said Juan Carlos Hidalgo, West Coast VP of Programming at Spanish Broadcasting System.

“Over the 9 years that AEG Live has been producing the event, this was its biggest year yet. We were proud to bring together a stellar line-up of the hottest new generation acts, as well as established heavy hitters in the Latin and General market space. Along with exciting surprise guests, the 4 hour high energy party had all of STAPLES on their feet for a party you didn’t want to miss,” stated Hans Schafer, Director of Latin Talent at AEG Live / Goldenvoice.

Calibash 2016 was sponsored by Bud Light, McDonalds, Southern CA Toyota Dealers, Jack Daniels, Vallarta Supermarkets, Open Road Films, LA Care Covered, Pampers, Vicks Vapor and Ford. Continue the conversation about Calibash 2016 on social media using #Calibash2016.

About Spanish Broadcasting System, Inc.
Spanish Broadcasting System, Inc. is the largest publicly traded Hispanic-controlled media and entertainment Company in the United States. SBS owns and operates 20 radio stations in the top U.S. Hispanic markets of New York, Los Angeles, Miami, Chicago, San Francisco and Puerto Rico, airing the Tropical, Mexican Regional, Spanish Adult Contemporary, Spanish Oldies and Urbano format genres. SBS also operates AIRE Radio Networks, a national radio platform that creates, distributes and markets leading Spanish-language radio programming to over 100 affiliated stations reaching 88% of the U.S. Hispanic audience. The Company also owns and operates MegaTV, a television operation with over-the-air, cable and satellite distribution and affiliates throughout the U.S. and Puerto Rico. SBS also produces live concerts and events and owns 21 bilingual websites, including Lamusica.com, an online destination and mobile app providing content related to Latin music, entertainment, news and culture. For more information, visit us online at www.spanishbroadcasting.com.

About AEG Live
AEG Live, the live-entertainment division of Los Angeles-based AEG, is dedicated to all aspects of live contemporary music performance. AEG Live is comprised of touring, festival, broadcast, merchandise and special event divisions, fifteen regional offices and owns, operates or exclusively books thirty-five state-of-the-art venues. The current and recent concert tour roster includes artists such as Alicia Keys, American Idols, Bon Jovi, Carrie Underwood, Daughtry, Enrique Iglesias, Jennifer Lopez, Justin Bieber, Kenny Chesney, Leonard Cohen, Paul McCartney, Taylor Swift, The WHO, Trey Songz and Juanes. The company is also currently producing residency shows at The Colosseum at Caesars Palace in Las Vegas including Celine Dion, Rod Stewart and Shania Twain and is the exclusive promoter at The Joint at Hard Rock Hotel & Casino Las Vegas. AEG Live is also the largest producer of music festivals in North America from the critically acclaimed Coachella Valley Music & Arts Festival to Stagecoach Country Music Festival and New Orleans Jazz & Heritage Festival. www.aeglive.com

Media Contacts:

Vladimir Gomez – Director of Communications & National Promotions – Spanish Broadcasting System, Inc. (SBS) – vgomez@sbscorporate.com – (786) 394-9000 ext. 1144

Daniel Morales – Tapiz Media – danielmorales@tapizmedia.com

(CVLT) Announces Global Customer Momentum

— Growth seen in all regions, across a variety of industries —

TINTON FALLS, N.J., Jan. 27, 2016  — Commvault (NASDAQ: CVLT), a global leader in enterprise data protection and information management, today announced continued customer momentum driven by the increased demand for Commvault data management solutions that span virtual, cloud, SaaS and traditional on premise to solve complex challenges caused by rapidly changing technology, tightening resource requirements, and ever-expanding volumes of data.

New and existing customers that have expanded their investment into Commvault’s portfolio of data management solutions and/or services in Q3 FY 2016 include, but are not limited to, the following organizations:

• BP²  – BNP Paribas Partners for Innovation
• CIECH Group
• City of Seattle
• Dataline
• DataSpring
• Guthrie Healthcare Systems
• Hero Cycles Limited & Associates
• Metropolitan Council of Minnesota
• NTT Data
• Reasonnet
• Tinkoff Bank
• University of Melbourne

“Data backup and protection is critical for high-availability datacenters,” said Martin Smekal, CEO of DataSpring. “That was the main reason for choosing Commvault, as it will allow us to offer the best services for backup, protection and deduplication in cloud environments with Virtual infrastructure friendly licensing policies.”

Following the launch of the Commvault Data Platform and an innovative software and service portfolio on October 20, 2015, these organizations are leveraging a variety of solutions and services to activate their data, unlock useful business insights and drive value from their new technology investments in Commvault.

“We are excited to bring on these customers in our 3^rd quarter and believe our growth speaks volumes about Commvault’s ability to meet emerging data management requirements in the marketplace today,” said N. Robert Hammer, chairman, president and CEO of Commvault. “We look forward to continuing this momentum based on the recent launch of our market leading Commvault Data Platform and next generation software, which provide organizations with a modern, holistic data management solution to tackle emerging and existing challenges facing customers today.”

For more information on how to become a Commvault customer, please visit: http://www.commvault.com

About Commvault
Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform modern data environments. With solutions and services delivered directly and through a worldwide network of partners and service providers, Commvault solutions comprise one of the industry’s leading portfolios in data protection and recovery, cloud, virtualization, archive, file sync and share. Commvault has earned accolades from customers and third party influencers for its technology vision, innovation, and execution as an independent and trusted expert. Without the distraction of a hardware business or other business agenda, Commvault’s sole focus on data management has led to adoption by companies of all sizes, in all industries, and for solutions deployed on premise, across mobile platforms, to and from the cloud, and provided as-a-service. Commvault employs more than 2,000 highly skilled individuals across markets worldwide, is publicly traded on NASDAQ (CVLT), and is headquartered in Tinton Falls, New Jersey in the United States. To learn more about Commvault — and how it can help make your data work for you — visit commvault.com.

Safe Harbor Statement: Customers’ results may differ materially from those stated herein; Commvault does not guarantee that all customers can achieve benefits similar to those stated above. This press release may contain forward-looking statements, including statements regarding financial projections, which are subject to risks and uncertainties, such as competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of software products and related services, general economic conditions and others. Statements regarding Commvault’s beliefs, plans, expectations or intentions regarding the future are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from anticipated results. Commvault does not undertake to update its forward-looking statements. The development and timing of any product release as well as any of its features or functionality remain at our sole discretion.

©1999-2016 Commvault Systems, Inc. All rights reserved. Commvault, Commvault and logo, the “C hexagon” logo, Commvault Systems, Solving Forward, SIM, Singular Information Management, OnePass, Commvault Galaxy, Unified Data Management, QiNetix, Quick Recovery, QR, CommNet, GridStor, Vault Tracker, InnerVault, Quick Snap, QSnap, IntelliSnap, Recovery Director, CommServe, CommCell, ROMS, Commvault Edge, and CommValue are trademarks or registered trademarks of Commvault Systems, Inc. All other third party brands, products, service names, trademarks, or registered service marks are the property of and used to identify the products or services of their respective owners. All specifications are subject to change without notice.

(MNKD) to Hold Investor Conference Call on February 3, 2016

VALENCIA, Calif., Jan. 27, 2016  — MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 3, 2016.

Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer and Chief Medical Officer, Raymond Urbanski.

To view and listen to the webcast, visit MannKind’s website at http://www.mannkindcorp.com and click on the “MannKind 2/3/16 Conference Call” link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 41729996. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4172 9996#. A replay will also be available on MannKind’s website for 14 days.

As with past calls, the Company will take live questions from covering analysts.  However, departing slightly from past practice for this call, stockholders who wish to submit questions in advance of the call should email them to ir@mannkindcorp.com.

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes.  MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Company Contact:
Matthew J. Pfeffer
Chief Executive Officer
661-775-5300
mpfeffer@mannkindcorp.com

(YRCW) Adds Former Senior Con-way Freight and FedEx Freight Executives

Also Introduces New Senior VP of Sales and Marketing

OVERLAND PARK, Kan., Jan. 26, 2016  — YRC Freight, a subsidiary of YRC Worldwide (NASDAQ:YRCW), recently announced the addition of senior executives from Con-way Freight and FedEx Freight with more than 80 years’ combined experience in the freight industry to its leadership team.

Chet Richardson has been named the Vice President of Transportation. Chet is a former Con-way Freight executive with 31 years’ experience in the LTL industry. During his time at Con-way Freight, he served as Service Center Manager, Region Manager, as well as Director and Vice President of Linehaul.

Paul Lorensen will lead the central divisions operations as Division Vice President. Lorensen comes to YRC Freight from Con-way Freight, where he most recently served as Central Area Vice President of Operations. Prior to that position, Lorensen managed several terminals and also served in several roles for Con-way Freight, including Director of Operations, Director of Quality, and Director of Solutions Engineering. He has 31 years’ industry experience.

Don Hinkle was named the new Vice President of Equipment Services. Hinkle has spent more than 23 years in all areas of terminal operations, as well as fleet maintenance. A previous YRC Freight employee, Hinkle returns to the company following 13 years with FedEx Freight. During his time at FedEx Freight, Hinkle held officer positions including Vice President of Fleet Maintenance, Safety and Transportation, and Vice President of Transportation.

The company also named Tim Haitz as the new Senior Vice President of Sales and Marketing. A 30-year YRC Freight veteran, Haitz has served primarily in sales roles, including his previous position as Vice President of Sales. He has previously worked as Terminal Manager, Vice President of Sales, and Corporate Account Executive.  Tim was promoted to this role after Bill Crowe, a 30-year veteran of YRC Freight, announced his retirement.

Darren Hawkins, President of YRC Freight, said the changes were a symbol of the momentum the company has gained over the past few years and a testament to the quality of professionals that are reaching out to YRC Freight.  “As a result, I am pleased to announce these additions to our team. It is a priority to invest in the people, technology and talent to drive the company forward,” Hawkins said. “The addition of these highly experienced and industry respected professionals demonstrates the investments we are making in our people and our company. Now is the time to be excited about YRC Freight.”

About YRC Freight

YRC Freight, a leading transporter of industrial, commercial and retail goods, specializes in less-than-truckload (LTL) shipping solutions for businesses. Based in Overland Park, Kan., YRC Freight provides comprehensive North American coverage and offers a broad portfolio of LTL services to bring flexibility and reliability to customers’ supply chains. For more information, visit www.yrcfreight.com.

Follow YRC Freight on Twitter: http://twitter.com/yrcfreightltl

About YRC Worldwide

YRC Worldwide Inc., headquartered in Overland Park, Kan., is the holding company for a portfolio of less-than-truckload (LTL) companies including YRC Freight, YRC Reimer, Holland, Reddaway, and New Penn. Collectively, YRC Worldwide companies have one of the largest, most comprehensive LTL networks in North America with local, regional, national and international capabilities. Through its team of experienced service professionals, YRC Worldwide companies offer industry-leading expertise in flexible supply chain solutions, ensuring customers can ship industrial, commercial and retail goods with confidence. Please visit www.yrcw.com for more information.

Media Contact: 
Mike Kelley
913-696-6121
mike.kelley@yrcw.com